Table 2.

Summary of the data collection per study’s stage

	Stage 1	Stage 2	Stage 3
Sociodemographic and anthropometric characteristics	×
Brief PA17 18 assessment	×	×
Respiratory symptoms (wheeze, breathlessness)	×	×	×
CAPTURE15	×
mMRC16	×
Diagnosis of chronic respiratory disease	×	×	×
Comorbidities and allergies	×	×	×
Smoking habits and ETS	×	×
A2 Score14	×
Family history of asthma	×	×
Age of asthma onset		×
Inhaler prescription/use	×
Mini-AQLQ29 30		×
EQ-5D31		×
Signs of asthma		×
CARAT21		×	×
Asthma control (according to GINA)		×	×
Asthma pharmacological treatment		×	×*
Inhalation technique		×
Adherence to inhaled medication		×	×*
Other treatments		×	×
No of exacerbations		×	×*
No of visits to emergency room		×	×*
No of hospital admissions and length of hospital stay		×	×*
No of unscheduled consultations		×	×*
No of consultations primary care team		×	×*
Referral for specialist care		×	×*
Standard measurements (blood pressure, height, weight)		×
Pre-BD and post-BD32 lung function		×
Pulmonary diagnostic tests (previously performed)			×
FeNO33		×
Peripheral blood eosinophil and neutrophil counts		×
Use of health and fitness apps	×	×
CARATm app use and opinion			×

*In the previous 3 and 12 months.

A2 Score, A2 adult asthma score; CAPTURE, COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk; CARAT, Control of Allergic Rhinitis and Asthma Test; CARATm, Caracteristicas Auto-reportadas de Asma em Tecnologias Móveis; EQ-5D, European Quality of Life Five Dimension; ETS, Environmental tobacco smoke; FeNO, Fractional exhaled nitric oxide; Mini-AQLQ, Mini Asthma Quality of Life Questionnaire; mMRC, Modified British Medical Research Council; PA, Brief physical activity assessment; pre-BD and post-BD, Spirometry prebronchodilator and postbronchodilator.